Dr. Reddy’s Q2 FY26 Results: Revenue Rises 9.8% YoY to ₹8,805 Crore; Profit at ₹1,437 Crore

Hyderabad, October 24 – Dr. Reddy’s Laboratories Ltd (NSE: DRREDDY, BSE: 500124, NYSE: RDY) reported its Q2 FY26 results. The company delivered strong performance in the quarter ended September 30, 2025, posting near-double-digit growth and steady profitability across markets.

Market Snapshot

As of October 24, 2025, shares of Dr. Reddy’s Laboratories Limited closed at ₹1,282.70, up by 0.26%, or ₹3.30. The shares of the company had a slow trading day, with total traded volume and traded value standing at 11.68 lakh shares and ₹149.56 crore, respectively. The total market cap for the company stood at ₹1,07,055.91 crore.

Key Financial Highlights

The company reported steady revenue growth in Q2 FY26, rising nearly 10% year-on-year. The growth was supported by consistent demand across key verticals. On the other hand, EBITDA remained stable at 26.7%, matching the previous quarter but slightly below last year. Profit before tax also declined slightly by 4%, while net profit improved 14% year-on-year, indicating efficient operational management.

Segment-Wise Performance

The company reported strong Q2 FY26 performance, with ₹7,850 crore in revenue from Global Generics, while its PSAI segment revenue rose to ₹945 crore. The company also expanded its portfolio through the Stugeron® acquisition, new product launches, and key pipeline milestones, including Semaglutide approval and Denosumab biosimilar progress.

ESG & Compliance

The company maintained its MSCI ESG Rating ‘A’ for the second consecutive year. It also earned LEED Platinum certification for its FTO-11 (Srikakulam) facility, India’s first pharma unit to achieve this distinction. Further, the company’s Morningstar Sustainalytics rating improved to 18.4 (Low Risk).

Management Outlook

The company had an overall positive outlook towards its Q2 FY26 results. Talking about the future prospects, the company stated that it is focused on strengthening its core generics and biosimilars portfolio, advancing key pipeline assets like Semaglutide and Abatacept, and augmenting growth through selective M&A and in-licensing opportunities. Overall, the company aims to maintain a balanced mix of geographies and product lines while driving operational efficiencies and sustainability initiatives.

REF: https://nsearchives.nseindia.com/corporate/DRREDDY_24102025165527_SEintimation24102025_Investor_presentation_signed.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations